Format

Send to

Choose Destination
Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6.

Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Author information

1
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Unit 0107, Houston, TX 77030, USA.

Abstract

This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.

KEYWORDS:

Cell signaling; Molecular targeted therapy; PI3K/Akt/mTOR signaling pathway; PTEN

PMID:
24012393
PMCID:
PMC3811932
DOI:
10.1016/j.soc.2013.06.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center